2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clinical Colorectal Cancer 2017, 17: e121-e125. PMID: 29233486, PMCID: PMC6598683, DOI: 10.1016/j.clcc.2017.10.008.Peer-Reviewed Original ResearchConceptsPathologic complete responseAdvanced rectal cancerNeoadjuvant chemoradiationRectal cancerInduction chemotherapyKRAS wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerThree-year disease-free survivalLocally Advanced Rectal CancerMetastatic colorectal cancerDisease-free survivalPhase III trialsAdequate hematologicEligible patientsBowel obstructionSame regimenIII trialsPerformance statusRenal functionComplete responseImproved survivalClinical outcomesMicroscopic cancerRectal adenocarcinomaPatient eligibility
2009
T1555 Outcomes from Liver Resection for Metastatic Colorectal Cancer in the Age of FOLFOX Chemotherapy
Sally M, Orloff S, Sheppard B, Khan S, Billingsley K. T1555 Outcomes from Liver Resection for Metastatic Colorectal Cancer in the Age of FOLFOX Chemotherapy. Gastroenterology 2009, 136: a-910. DOI: 10.1016/s0016-5085(09)64208-6.Peer-Reviewed Original ResearchMetastatic colorectal cancerFOLFOX chemotherapyLiver resectionColorectal cancerResectionChemotherapyCancer
2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimens
2006
Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study
Whitehead R, McCoy S, Wollner I, Wong L, Harker W, Hoff P, Gold P, Billingsley K, Blanke C. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study. Journal Of Clinical Oncology 2006, 24: 3598-3598. DOI: 10.1200/jco.2006.24.18_suppl.3598.Peer-Reviewed Original ResearchPrior chemotherapy regimensAdvanced colorectal cancerPhase II trialColorectal cancerEligible patientsChemotherapy regimensII trialPerformance statusSouthwest Oncology Group studyCommon grade 2Prior chemotherapy regimenZubrod performance statusMetastatic colorectal cancerMonths overall survivalColorectal cancer patientsSerum magnesium levelsSignificant anti-tumor activityKaplan-Meier estimatesAdditional active agentsAnti-tumor activityHistone deacetylase inhibitorsMurine model systemBaseline labsMeasurable diseasePrior regimens